These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 12002985)

  • 21. Meningococcal disease in Canada: surveillance summary to 1987.
    Varughese PV
    CMAJ; 1989 Sep; 141(6):567-9. PubMed ID: 2505917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meningococcal disease and prevention at the Hajj.
    Borrow R
    Travel Med Infect Dis; 2009 Jul; 7(4):219-25. PubMed ID: 19717104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of meningococcal serogroup C conjugate vaccine in Scotland.
    Mooney JD; Christie P; Robertson C; Clarke SC
    Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ACIP recommends meningococcal vaccine for adolescents and college freshmen.
    Mich Med; 2005; 104(4):22. PubMed ID: 16053236
    [No Abstract]   [Full Text] [Related]  

  • 25. [Meningococcal disease. new prevention strategies].
    Soult Rubio JA; Muñoz Sáez M; López Castilla JD
    An Esp Pediatr; 2001 Jan; 54(1):65-8. PubMed ID: 11181197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The meningococcal vaccine--public policy and individual choices.
    Offit PA; Peter G
    N Engl J Med; 2003 Dec; 349(24):2353-6. PubMed ID: 14668463
    [No Abstract]   [Full Text] [Related]  

  • 27. Meningococcal vaccine evolution.
    Bona G; Guidi C
    J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination].
    Gutiérrez Rodríguez MA; Ramírez Fernández R; García Gutiérrez J; Moreno Civantos A; Hernando García M; Arce Arnáez A; Sendra Gutiérrez JM; Bueno Vallejos R
    Rev Esp Salud Publica; 2000; 74(4):397-403. PubMed ID: 11031849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The strategy to control New Zealand's epidemic of group B meningococcal disease.
    O'Hallahan J; Lennon D; Oster P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meningococcus C vaccination programme.
    Murphy JF
    Ir Med J; 2000 Sep; 93(6):164. PubMed ID: 11105434
    [No Abstract]   [Full Text] [Related]  

  • 32. Meningococcal infections in Quebec--1991-92.
    Lavigne P; Boulianne N; Fortin C; Naccache H; Douville-Fradet M
    Can Commun Dis Rep; 1992 Aug; 18(15):113-6. PubMed ID: 1290994
    [No Abstract]   [Full Text] [Related]  

  • 33. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meningococcal disease in São Paulo, Brazil.
    Costa W; Sacchi CT; Ramos S; Milagres L; Prigenzi LS
    NIPH Ann; 1991 Dec; 14(2):215-6; discussion 216-8, 222-4. PubMed ID: 1812434
    [No Abstract]   [Full Text] [Related]  

  • 35. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection.
    Pace D
    Curr Opin Mol Ther; 2009 Dec; 11(6):692-706. PubMed ID: 20072946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines.
    Ladhani SN; Flood JS; Ramsay ME; Campbell H; Gray SJ; Kaczmarski EB; Mallard RH; Guiver M; Newbold LS; Borrow R
    Vaccine; 2012 May; 30(24):3710-6. PubMed ID: 22429756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meningococcal disease: the advances and challenges of meningococcal disease prevention.
    Yogev R; Tan T
    Hum Vaccin; 2011 Aug; 7(8):828-37. PubMed ID: 21832882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
    Bolland M
    N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
    [No Abstract]   [Full Text] [Related]  

  • 40. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.
    Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M
    Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.